ESCMID Global 2027
09–13 April 2027 | Stockholm, Sweden
If you’re planning infectious disease development in 2027–2028, ESCMID Global is an ideal venue to test endpoints, operational feasibility, and country start-up timelines before finalizing your pivotal plan.
What sponsors can expect when they meet PSI CRO at ESCMID Global
You’ll have a delivery-focused discussion about what it takes to run global phase 2–3 infectious disease trials with reliable start-up and enrollment across regions. PSI brings deep operational experience from pivotal anti-infective programs, including providing pivotal trial data that contributed to FDA approval for 50% of all novel antibiotics since 2010.
We can work together on:
- Feasibility that translates into real enrollment (site mix, competition mapping, and activation sequencing by country)
- The realities of start-up and regulatory requirements for complex ID protocols (including IP logistics, microbiology lab workflows, and sample handling)
- Site support models that safeguard data quality and timelines for high-burden indications
Stop by to talk about infectious disease trial delivery and see how PSI uses SYNETIC™ (agentic AI site intelligence across 500,000+ institutions and over 3 million study sites) to identify locations with the right patient flow, diagnostics, and operational readiness for anti-infective studies.
